glp-1 buddy Dr. Stephanie's Protein Drink Mix, Strawberry Watermelon, 10 CT GLP-1 Companion Health Pack Daily

Past performance does not guarantee future results

doi: 10.1016/j.autrev.2018.10.001

On Wegovy (semaglutide 2.4 mg, approved for chronic weight management): The FDA-approved prescribing information for Wegovy discloses that in the SELECT cardiovascular outcomes trial - a large study conducted in adults with established cardiovascular disease - hip and pelvis fractures were reported more often in female patients on Wegovy than in those on placebo: 1% (24/2,448) versus 0.2% (5/2,424)

This guarantees quality control, consistent dosing, and safety under full FDA scrutiny, enabling you to trust your treatment plan wholly

After 52 weeks patients continued on the once weekly exenatide maintained an A1C improvement (2.0%) while those switching from twice daily to once weekly further reduced A1C to achieve a similar reduction in A1C as those originally on exenatide once weekly